Corient Private Wealth
ORIC icon

Corient Private Wealth’s Oric Pharmaceuticals ORIC Stock Holding History

Corient Private Wealth’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,512
Closed -$102K – 2951
2025
Q4 		$102K Buy
+12,512
New +$144K ﹤0.01% 2545

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Corient Private Wealth's ORIC Position: Q1 2026 in Review

Corient Private Wealth sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 12,512 shares — an estimated $102K sold.

Corient Private Wealth first reported a position in ORIC in Q4 2025 and held it in 1 quarter. The position peaked at $102K in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Corient Private Wealth reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Corient Private Wealth sold 12,512 Oric Pharmaceuticals shares in Q1 2026, an estimated $102K.
  • Corient Private Wealth first reported a position in Oric Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Corient Private Wealth's Oric Pharmaceuticals position peaked at $102K in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.